Skip to main content

PerkinElmer Offering $500M in Senior Notes to Fund Caliper Purchase

NEW YORK (GenomeWeb News) – PerkinElmer today announced the pricing of a $500 million offering to be used in part to fund its $600 million purchase of Caliper Life Sciences.

The senior notes carry an aggregate principal amount of 5 percent and are due 2021 at an issue price of 99.372 percent of the principal amount. The issuance of the notes is expected to close Oct. 25. The notes will pay interest on a semi-annual basis.

The joint book-running managers on the offering are Merrill Lynch, Pierce, Fenner & Smith; Barclays Capital; and Deutsche Bank Securities.

The purchase of Caliper was announced last month. Earlier this week, the deal cleared regulatory hurdles in the US and Germany and now awaits shareholder approval and other conditions.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.